2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $1.2B | $1.5B | $1.5B | $872M | $996M |
Cost of Revenue | $25M | $39M | $46M | $42M | $27M |
Gross Profit | $1.2B | $1.5B | $1.5B | $830M | $968M |
Gross Profit % | 98% | 98% | 97% | 95% | 97% |
R&D Expenses | $0.37 | $0.47 | $0.62 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $432M | $657M | $904M | -$556M | -$2.4B |
Dep. & Amort. | $276M | $334M | $346M | $616M | $454M |
Def. Tax | $22M | $43M | $11M | -$167M | $0 |
Stock Comp. | $47M | $52M | $49M | $33M | $33M |
Chg. in WC | $17M | $13M | $30M | -$125M | -$16M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $550M | $459M | $236M | $250M | $332M |
ST Investments | $0 | $0 | $1.7B | $0 | $0 |
Cash & ST Inv. | $550M | $459M | $236M | $250M | $332M |
Receivables | $1.4B | $2.1B | $1.2B | $681M | $737M |
Inventory | $1 | $1.2B | -$305M | $0 | $0 |
MPW executed approximately $3 billion in liquidity transactions in 2024, surpassing their initial $2 billion target, and issued $2.5 billion in seven-year secured bonds at a blended coupon of 7.88%, covering debt maturities through 2026.
The company expects total annualized cash rent of more than $1 billion once new tenants are fully ramped, with contractual cash rent from recently transitioned facilities ramping up to $40 million per quarter by October 2026.
MPW reported a GAAP net loss of $413 million for Q4 2024, impacted by impairments and adjustments related to Prospect Medical Group's Chapter 11 bankruptcy, with normalized FFO of $0.18 per share for the quarter.
The company has approximately $1.4 billion in liquidity and plans to explore additional asset sales, joint ventures, and portfolio repositioning to further improve FFO and leverage metrics.
MPW's unencumbered asset pool remains significant, providing flexibility for future secured financings or asset sales, with the portfolio weighted slightly more toward U.S. assets.